Association of MMP-9 promoter polymorphism and breast cancer among Iranian patients
Keywords:
breast cancer, gene polymorphism, Iran, PCR-RFLPAbstract
Background and aims: Breast cancer is one of the most common cancers in women population. This cancer is influenced by environmental and genetic factors. MMP-9, a member of MMPs family, is located on 20 q11.2- q13.1 and encodes Gelatinase B, a 92 KDa protein which is able to degrade collagen IV, matrix proteoglycan core and elastin. Over expression of MMP-9 has been shown in some cancers. MMP-9 is involved in the metastasis and cancerous cells migration. MMP-9 promoter polymorphism (-1562 C>T) is a candidate for cancer susceptibility. It is likely that T allele impedes recruitment of repressor proteins and causes gene over expression in T allele carriers. In the present case-control study we investigate whether MMP-9 promoter polymorphism (-1562C>T) is associated with breast cancer. Methods: A total of 216 Azeri women including 104 patients and 112 healthy women were enrolled in the study. Blood sampling was done after taking a written consent. Genomic DNA was extracted and its purity was determined on 1% agarose gel. Then the given polymorphism was determined by PCR- RFLP method using SphI. Results: The results showed that T allele and CT genotype are more frequent in the patients as compared to the control group, but there are not significant differences between two groups (P=0.1). Conclusion: It is suggested that MMP-9 polymorphism (-1562C>T) is not associated with the breast cancer occurrence in our population. However, further studies in larger populations including other genetic and environmental factors are required to achieve conclusion.
Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.